NEW YORK--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (“HepaLife”), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, today announced its intention to pursue the development of a transdermal pain patch. HepaLife’s subsidiary, Alliqua BioMedical, Inc. (“Alliqua”), recently retained Jeiven Pharmaceutical Consulting, Inc. (“Jeiven”) to assist it in this new product development.
